The purpose of this study is to explore the role of OPN in epithelialmesenchymal transition (EMT) in HER2 positive GCs.
Pathol Res Pract. 2021 Nov;227:153643.
Intratumoral EML4-ALK isoforms may predict the efficacy of targeted therapy in ALK-rearranged NSCLC. Temporal changes of intratumoral fusion isoforms may result from differential selection pressures that a drug might have on one isoform over another. Larger studies on fusion heterogeneity using RNA sequencing are warranted.
J Thorac Oncol. 2021 Oct 6;S1556-0864(21)03219-6.
"Toripalimab plus chemotherapy showed a promising anti-tumor activity with acceptable safety profiles as the secondline
setting in patients with EGFR-mutant NSCLC. DSPP mutation might serve as a potential biomarker for this combination."
Signal Transduct Target Ther. 2021 Oct 15;6(1):355.
These results suggested that FNA washout precipitation specimens might be a valuable supplementary sample type for detecting the BRAF V600E mutation in patients with thyroid nodules, especially with thyroid capsule invasion.
Technol Cancer Res Treat. Jan-Dec 2021;20:15330338211057982.
Our present results suggest that ctDNA is a promising method for the detection of mutation spectrum and serves as a biomarker for disease monitoring and predicting clinical recurrence.
Br J Haematol. 2021 Oct 19.
PD-L1 may be an effective therapeutic target for cervical SCNC. Cervical SCNC is a MMR-stable tumor and lacks NTRK gene fusion. IHC isn’t a reliable method in the detection of NTRK gene fusion in cervical SCNC.
Front Oncol. 2021 Oct 21;11:752453.